Perceptive Advisors

MeiraGTx is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company has a diverse pipeline that includes several ongoing clinical programs focused primarily on treating conditions related to the eye, salivary gland, and central nervous system. Key product candidates include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, leveraging its expertise in viral vector design and gene therapy manufacturing. With a portfolio approach to technology development, the company plans to expand its focus to include additional gene therapy treatments for various serious diseases in the future.

Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis.

Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.

Acrivon Therapeutics is a biotech company specializing in drug development through early clinical treatment success.

Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Rain Therapeutics Inc. is a biotechnology company focused on developing targeted therapies for cancer patients, particularly those with unmet medical needs. Established in 2017 and based in Newark, California, the company specializes in small molecule therapeutics. Its lead product, RAIN-32, is a small molecule MDM2 inhibitor aimed at treating well-differentiated and de-differentiated liposarcoma. Additionally, Rain Therapeutics is developing tarloxotinib, a hypoxia-activated pan-HER inhibitor currently undergoing clinical trials for non-small cell lung cancer. The company emphasizes identifying cancers driven by specific oncogenic mutations and evaluates sub-populations where existing treatment options are inadequate. Through collaboration with a global network of scientific and thought leaders, Rain Therapeutics seeks to align its therapeutic innovations with the needs of these cancer populations.

Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing targeted gene therapy products using evolved adeno-associated virus vectors. The company has a diverse portfolio focusing on three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Key product candidates include 4D-125, currently in a Phase I/II clinical trial for treating X-linked retinitis pigmentosa; 4D-110, in a Phase I trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is developing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The company aims to address unmet medical needs through its innovative gene therapies.

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer.

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Saama is the number one AI-powered clinical analytics cloud platform company, unleashing wisdom from data to deliver better business outcomes for the life sciences industry. Saama’s unified, AI-driven clinical data analytics platform seamlessly integrates, curates, and animates unlimited sources of structured, unstructured, and real-world data to deliver actionable insights across all therapeutic areas. The award-winning platform gives unprecedented real-time visibility into clinical data, enabling sponsors to file New Drug Applications (NDAs) more efficiently to bring drugs to market faster and at lower costs. For more information, visit http://www.saama.com.

Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.

BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.

4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing targeted gene therapy products using evolved adeno-associated virus vectors. The company has a diverse portfolio focusing on three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Key product candidates include 4D-125, currently in a Phase I/II clinical trial for treating X-linked retinitis pigmentosa; 4D-110, in a Phase I trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is developing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The company aims to address unmet medical needs through its innovative gene therapies.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Rain Therapeutics Inc. is a biotechnology company focused on developing targeted therapies for cancer patients, particularly those with unmet medical needs. Established in 2017 and based in Newark, California, the company specializes in small molecule therapeutics. Its lead product, RAIN-32, is a small molecule MDM2 inhibitor aimed at treating well-differentiated and de-differentiated liposarcoma. Additionally, Rain Therapeutics is developing tarloxotinib, a hypoxia-activated pan-HER inhibitor currently undergoing clinical trials for non-small cell lung cancer. The company emphasizes identifying cancers driven by specific oncogenic mutations and evaluates sub-populations where existing treatment options are inadequate. Through collaboration with a global network of scientific and thought leaders, Rain Therapeutics seeks to align its therapeutic innovations with the needs of these cancer populations.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.

BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

Champions Oncology, Inc. specializes in developing technology solutions and products aimed at personalizing the treatment of cancer. The company employs its Tumorgraft Technology Platform, which involves implanting human tumors in immune-deficient mice, to provide Personalized Oncology Solutions (POS). This platform enables physicians to tailor treatment options based on specific tumor data obtained from drug panels. Additionally, Champions Oncology offers Translational Oncology Solutions to assist pharmaceutical and biotechnology companies in their drug development processes. The company's product offerings include TumorGraft implants and drug panels that evaluate the response of a patient's tumor to various oncology drugs or combinations. Champions Oncology markets its products through online channels, referrals, and a dedicated sales team. Founded by leading experts in cancer research and treatment, the company is headquartered in Hackensack, New Jersey, and was incorporated in 1985.

Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of oncology and hematology drug products. The company is advancing several key therapies, including ROLONTIS, a long-acting granulocyte colony-stimulating factor aimed at treating chemotherapy-induced neutropenia; Poziotinib, an irreversible tyrosine kinase inhibitor targeting specific mutations in non-small cell lung cancer; and an Anti-CD20-IFNα fusion molecule, currently in Phase I trials for relapsed or refractory non-Hodgkin’s lymphoma. Spectrum has established various partnerships, including co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd., as well as licensing agreements with notable institutions such as The University of Texas M.D. Anderson Cancer Center and ImmunGene, Inc. Founded in 1987 and headquartered in Henderson, Nevada, the company was previously known as NeoTherapeutics, Inc. before adopting its current name in December 2002.